New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Form SCHEDULE 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.
-
SetPoint Medical Raises $140 Million in Private Financing and Expands Leadership Team to Support Commercialization of Rheumatoid Arthritis Therapy
-
NeueHealth Reports Second Quarter 2025 Results
-
August Raises $7M to Deliver Configurable Legal AI to Midsize Firms
-
NEA-Backed NG.CASH Announces the Close of $26.5M Series B
-
Healthcare-Focused Secondaries Manager Revelation Partners Names Rob Rein as Principal and Courtney Munley and Vicky Valverde as Senior Associates
-
Veza Simplifies Oracle Access Governance with Unified Access Visibility, Intelligence, and Least Privilege Management
-
Firestorm Labs Announces $47 million Series A Funding to Accelerate Growth and Innovation in Defense Technology
-
Tailor Expands Series A to $22M with Private-Public Support
-
Foresight Raises $5.5M Seed Round to Bring Unified Data and AI to the Private Market
-
SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines
-
NEA Promotes Madison Faulkner and Mustafa Neemuchwala to Partner
-
THE POINTS GUY NAMES LIZA LANDSMAN AS CEO
-
SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients
-
Form SCHEDULE 13D/A BuzzFeed, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
ORIC Pharmaceuticals Inc. (ORIC) Announces $125 Million Private Placement at $6.50/sh
-
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing
-
Form SCHEDULE 13D/A Allakos Inc. Filed by: New Enterprise Associates 16, L.P.
-
AviadoBio Announces ASPIRE-FTD Phase 1/2 Clinical Trial in the UK at Cambridge University Hospitals NHS Foundation Trust, Cardiff and Vale University Health Board, and University College London
-
Samaya AI Announces $43.5m in Funding Led by NEA, Launches New AI Agent for Financial Services
-
Form SCHEDULE 13G/A Sagimet Biosciences Inc. Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Form SCHEDULE 13D/A Arcellx, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Form SCHEDULE 13D/A BuzzFeed, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
NeueHealth Reports First Quarter 2025 Results
-
Form SCHEDULE 13D/A Inventiva S.A. Filed by: New Enterprise Associates 17, L.P.
-
IONQ Inc (IONQ) Appoints Jordan Shapiro as President and General Manager, Quantum Networking
-
IonQ Appoints Jordan Shapiro to President and General Manager, Quantum Networking
-
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million
-
CHAOS Industries Raises $275 Million Series C to Advance Defense and National Security Technology Innovation
-
AviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN
-
Veza Raises $108 Million in Series D at $808 Million Valuation to Meet Global Demand for its Pioneering Identity Security Platform
-
Catheter Precision to Acquire Assets in Development for Late-Stage Treatment for Acute Decompensated Heart Failure
-
Aigen Launches Next Generation Element Robots for Weeding in Partnership with Bowles Farming Company
-
Jeffrey Immelt, Former GE Chairman & CEO, Appointed to Automation Anywhere's Board of Directors
-
NEA Welcomes Anna Golynskaya as Partner, Head of Capital Formation and LP Relations
-
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
-
Construct Capital Closes $300 Million Fund III to Transform Foundational Industries
-
Form SCHEDULE 13D/A BuzzFeed, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Canaccord Genuity Reiterates Hold Rating on Illumina (ILMN)
-
Canaccord Genuity Reiterates Hold Rating on Illumina (ILMN)
-
Illumina (ILMN) Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
-
Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
-
Second Front Systems Appoints Drew Hoffman as President and Chief Legal Officer
-
Form SCHEDULE 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.
-
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights
-
NeueHealth Reports Fourth Quarter and Full Year 2024 Results
-
Form SCHEDULE 13D/A BuzzFeed, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Form SCHEDULE 13D/A Senti Biosciences, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor
-
Tune Therapeutics Names John McHutchison as CEO and Chairman of the Board

